Voyager Therapeutics (NASDAQ:VYGR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock.

Several other brokerages have also commented on VYGR. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush reduced their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, November 10th. Finally, Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Voyager Therapeutics Stock Performance

NASDAQ VYGR traded down $0.46 during trading on Thursday, reaching $5.76. 403,619 shares of the company traded hands, compared to its average volume of 641,439. Voyager Therapeutics has a 1-year low of $5.67 and a 1-year high of $11.72. The stock’s 50 day moving average price is $6.63 and its two-hundred day moving average price is $7.52. The company has a market cap of $314.09 million, a price-to-earnings ratio of 8.11 and a beta of 0.89.

Insider Buying and Selling

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This represents a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC raised its holdings in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares during the period. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after buying an additional 702,030 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after acquiring an additional 1,000,000 shares during the last quarter. Great Point Partners LLC bought a new position in Voyager Therapeutics during the second quarter worth $12,668,000. Finally, Erste Asset Management GmbH bought a new position in Voyager Therapeutics during the third quarter worth $6,192,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.